FDA approves genetic test for lung cancer drug

The Food and Drug Administration says it approved a genetic test from Roche to help doctors identify patients who can benefit from a lung cancer drug made by Genentech.

The diagnostic test is the first approved to detect found in roughly 10 percent of patients with the most prevalent form of lung cancer, known as non-small cell lung cancer.

Patients who test positive for the mutation are more likely to respond to Genentech's drug Tarceva as a first-choice treatment, and the FDA expanded the drug's approval for that use in an announcement Tuesday. The drug was previously approved only as a second-line option after patients had failed to respond to chemotherapy.

Lung cancer is the deadliest form of cancer among both men and women in the U.S.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New treatment holds promise for resistant lung cancer

Apr 09, 2013

A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps ...

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments